Abstract 2663
Background
The oral chemotherapy trifluridine/tipiracil (FTD/TPI or TAS-102) is approved for treatment of previously treated mCRC patients (pts) beyond the second line, in the same setting as regorafenib. Optimal treatment sequencing between the two at this stage is not established. Here, a descriptive post hoc sub-group analysis assessed safety and efficacy of FTD/TPI in mCRC pts according to previous treatment with regorafenib in a preliminary analysis of the phase 3b PRECONNECT study (NCT03306394).
Methods
PRECONNECT is enrolling pts with histologically confirmed mCRC previously treated with available therapies, with an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0/1. Pts receive oral FTD/TPI (35 mg/m2 bid) on days 1–5 and 8–12 of each 28-day cycle. Of the 462 patients who received at least one dose at cutoff (1 Nov 2017), 166 (36%) were pretreated with regorafenib.
Results
Patient subgroups pretreated (n = 166) and non-pretreated (n = 296) with regorafenib were broadly similar, with a slight imbalance for RAS mutant status (61% vs 47%), left-sided tumour (58% vs 65%) and treatment line (12% vs 36% receiving FTD/TPI third line), respectively. There was no difference in rate of emergent or drug-related any grade adverse events (AEs), or drug-related grade ≥3 AEs in pts treated with FTD/TPI between the regorafenib pretreated and regorafenib non-pretreated subgroups (98% vs 96%; 77% vs 79%; and 54% vs 51%, respectively). The most common drug-related grade ≥3 AEs were neutropenia (43% vs 40%) and anemia (8% vs 7%). Median FTD/TPI treatment duration were 2.7 and 3.1 months, with a median PFS of 2.7 (95% CI 2.2-3.3) and 3.3 months (95% CI 2.8-3.7), disease control rate was 38% (95% CI 30–46) and 43% (95% CI 37-49) and median time to ECOG-PS ≥2 was 8.5 and 8.7 months in the regorafenib pretreated and regorafenib non-pretreated, respectively.
Conclusions
FTD/TPI may be used either before or after regorafenib with similar efficacy results making treatment safety profile and patient quality of life major points to determine treatment option in third-line for mCRC patients.
Clinical trial identification
EudraCT: 2016-002311-18.
Legal entity responsible for the study
Laboratoires Servier.
Funding
Laboratoires Servier.
Editorial Acknowledgement
Not applicable
Disclosure
J. Taieb: Honoraria speaker or advisory role: Servier, Roche, Lilly, Celgene, Shire, Amgen, Sanofi, Merck, Lilly, Sirtex. A. Falcone: Compensation for participation Advisory Boards, Research Grants to institution: Amgen, Bayer, Merck, MSD, Roche, Lilly, Servier, Bristol. S. Lonardi: Consulting or advisory role: Amgen, Bayer, Merck, Lilly; Speakers' bureau: Lilly; Roche, BMS; Research funding: Amgen. T.J. Price: Advisory board: Amgen (paid self), Merck, Roche, Takeda (paid self). J-B. Bachet: Honoraria: Amgen, Bayer, Celgene, Merck Serono, Roche, Shire, Servier. L. Wyrwicz: Funding or fees: Halozyme, Eisai, Merck. F. Ciardiello: Advisory board role: Servier, Merck, Roche, Amgen, Bayer, Symphogen. M. Becquart, N. Mounedji: Employee: Servier. E. Van Cutsem: Grants: Amgen, Bayer, BMS, Boehringer, Celgene, Ipsen, Lilly, Merck, MSD, Novartis, Roche, Servier; Honoraria: Bayer, BMS, Celgene, Lilly, Novartis, Servier.
Resources from the same session
3247 - Impact of delayed addition of anti-EGFR monoclonal antibodies on the outcome of first-line therapy in metastatic colorectal cancer patients: a retrospective registry-based analysis
Presenter: Tomas Buchler
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3415 - A multicenter phase II trial to evaluate the efficacy of mFOLFOX6+cetuximab as induction chemotherapy to achieve R0 surgical resection for advanced colorectal liver metastases (NEXTO trial)
Presenter: YUJIRO NISHIOKA
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2914 - Initial report of a phase I/II study of S-1 and irinotecan (IRIS) in combination with cetuximab in patients with wild-type RAS metastatic colorectal cancer
Presenter: Eiji Oki
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3704 - A multi-institutional randomized phase II study on the timing of Oxaliplatin plus 5-Fluorouracil (FOLFOX) for patients (pts) with operable stage III rectal cancer: The KIR Study.
Presenter: Petr Kavan
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1023 - Tumor Regression Grading After Preoperative Hyperfractionated Radiotherapy/ Chemoradiotherapy for Locally Advanced Rectal Cancers: A Phase III Clinical Study
Presenter: ADAM IDASIAK
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3506 - Short-Term radiotherapy plus chEmotherapy versus Long-term chemoradiotherapy in Locally Advanced Rectal cancer (STELLAR): a planned interim analysis
Presenter: Jing Jin
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
4390 - mFOLFOXIRI versus mFOLFOX6 as neoadjuvant chemotherapy in locally advanced rectal cancer: A Propensity Score Analysis from two prospective trials
Presenter: JianWei Zhang
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3412 - Phase 1/2 study of valproic acid (VPA) and short-course radiotherapy (SCRT) plus capecitabine (CAP) as preoperative treatment in low-moderate risk rectal cancer (V-shoRT-R3).
Presenter: Alfredo Budillon
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2096 - A classifier of 53BP1, immune score and texture analysis of MRI images can predict pathological response to chemoradiotherapy in locally advanced rectal cancer
Presenter: Hong Ma
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5127 - Mismatch repair deficient rectal cancer is resistant to induction combination chemotherapy
Presenter: Andrea Cercek
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract